2023
Characterization of the HLA-F ligandome in T-cell lymphoma
Mota I, Osean J, Song E, Clement C, Lenz J, Miller D, Inghirami G, Montagna C, Bouvier M, Iwasaki A, Santambrogio L. Characterization of the HLA-F ligandome in T-cell lymphoma. The Journal Of Immunology 2023, 210: 222.06-222.06. DOI: 10.4049/jimmunol.210.supp.222.06.Peer-Reviewed Original ResearchT-cell lymphoma cell linesHealthy donor PBMCsT cellsLymphoma cell linesHLA-FDonor PBMCsTumor-specific antigensCancer immune responseT-cell lymphomaTotal T cellsNK cell receptorsTumor-specific markersCell linesHLA-I moleculesPeptides to T cellsCancer immunotherapyNK cellsHLA haplotypesRegulating immunityTherapeutic targetPotential new classDNA integrityDNA methylation patternsPeptide repertoirePBMC
2020
Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity
Longbrake EE, Mao-Draayer Y, Cascione M, Zielinski T, Bame E, Brassat D, Chen C, Kapadia S, Mendoza JP, Miller C, Parks B, Xing D, Robertson D. Dimethyl fumarate treatment shifts the immune environment toward an anti-inflammatory cell profile while maintaining protective humoral immunity. Multiple Sclerosis Journal 2020, 27: 883-894. PMID: 32716690, PMCID: PMC8023410, DOI: 10.1177/1352458520937282.Peer-Reviewed Original ResearchConceptsDelayed-release dimethyl fumarateAbsolute lymphocyte countT cellsMedian absolute lymphocyte countEffector memory T cellsDimethyl fumarate treatmentPhase 3b studyTotal T cellsAdverse event ratesMemory T cellsProtective humoral immunityForms of MSDMF BIDLymphocyte subsetsAdverse eventsLymphocyte countTotal IgAImmune environmentImmunoglobulin levelsNaive CD4Sustained efficacyHumoral immunityFumarate treatmentSubclass levelsCount changes
2019
Apremilast mechanism of efficacy in systemic-naive patients with moderate plaque psoriasis: Pharmacodynamic results from the UNVEIL study
Strober B, Alikhan A, Lockshin B, Shi R, Cirulli J, Schafer P. Apremilast mechanism of efficacy in systemic-naive patients with moderate plaque psoriasis: Pharmacodynamic results from the UNVEIL study. Journal Of Dermatological Science 2019, 96: 126-133. PMID: 31787506, DOI: 10.1016/j.jdermsci.2019.09.003.Peer-Reviewed Original ResearchConceptsModerate plaque psoriasisIL-17APlaque psoriasisIL-22Week 16T cellsRegulatory T cell numbersT helper 17 (Th17) cellsEfficacy of apremilastIL-23 levelsTotal T cellsPlasma cytokine levelsRegulatory T cellsT cell numbersMedian percentage reductionPathogenesis of psoriasisSevere psoriasisCardiometabolic biomarkersClinical improvementCytokine levelsInflammatory biomarkersIL-17FWeeks 0Clinical trialsWeek 4
2017
Longitudinal Antibody Signatures Following FVIII Replacement Therapy in Previously Untreated Patients with Severe Hemophilia Α- New Insights from the Hemophilia Inhibitor PUP Study (HIPS)
Gangadharan B, Reipert B, Scheiflinger F, Bowen J, Donnachie E, van Draat K, Gruppo R, Klintman J, Male C, McGuinn C, Meeks S, Recht M, Ragni M, Yaish H, Shapiro A, Yee D, Radulescu V, Santagostino E, Brown D. Longitudinal Antibody Signatures Following FVIII Replacement Therapy in Previously Untreated Patients with Severe Hemophilia Α- New Insights from the Hemophilia Inhibitor PUP Study (HIPS). Blood 2017, 130: 88. DOI: 10.1182/blood.v130.suppl_1.88.88.Peer-Reviewed Original ResearchFVIII-specific antibodiesNon-neutralizing antibodiesPro-inflammatory TH17 cellsEntity's Board of DirectorsFVIII inhibitor developmentTotal T cellsFVIII inhibitorsT cellsCirculating immune cellsNK cellsTh17 cellsIgG subclassesInhibitor patientsIgG1 antibodiesExposure daysCSL BehringImmune cellsPUP studiesTiter of FVIII inhibitorsInhibitor developmentCirculating Th17 cellsHigh-titer inhibitorsFVIII replacement therapyAnti-FVIII antibodiesSevere hemophilia A
2013
Phosphatidylinositol 3-Kinase–Independent Signaling Pathways Contribute to ICOS-Mediated T Cell Costimulation in Acute Graft-Versus-Host Disease in Mice
Li J, Heinrichs J, Leconte J, Haarberg K, Semple K, Liu C, Gigoux M, Kornete M, Piccirillo C, Suh W, Yu X. Phosphatidylinositol 3-Kinase–Independent Signaling Pathways Contribute to ICOS-Mediated T Cell Costimulation in Acute Graft-Versus-Host Disease in Mice. The Journal Of Immunology 2013, 191: 200-207. PMID: 23729441, PMCID: PMC4318500, DOI: 10.4049/jimmunol.1203485.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAnimalsDisease Models, AnimalGene Knock-In TechniquesGraft vs Host DiseaseInducible T-Cell Co-Stimulator ProteinLymphocyte ActivationMiceMice, 129 StrainMice, Inbred BALB CMice, Inbred C57BLMice, KnockoutMice, TransgenicPhosphatidylinositol 3-KinaseSignal TransductionT-Lymphocyte SubsetsConceptsCD8 T cellsCD4 T cellsT cellsHost diseaseWild-type CD8 T cellsCD8 T cell compartmentAllogeneic bone marrow transplantationAcute Graft-VersusPathogenic potentialTotal T cellsAlloreactive T cellsBone marrow transplantationT cell compartmentWild-type T cellsIntracellular calcium mobilizationVivo pathogenic potentialT cell costimulationT cell activationKnockout T cellsAcute graftAcute GVHDGraft-VersusSevere GVHDGVHD modelMarrow transplantation
1996
Existence and Failure of T-Cell Homeostasis Prior to AIDS Onset in HIV-Infected Injection Drug Users
Galai N, Margolick J, Astemborski J, Vlahov D. Existence and Failure of T-Cell Homeostasis Prior to AIDS Onset in HIV-Infected Injection Drug Users. Clinical Immunology 1996, 79: 134-141. PMID: 8620619, DOI: 10.1006/clin.1996.0060.Peer-Reviewed Original ResearchConceptsInjection drug usersTotal T cellsT cell homeostasisT cellsHIV infectionAIDS onsetAIDS diagnosisHomosexual menDrug usersCurrent injection drug useSeropositive injection drug usersInjection drug useT cell levelsImportant prognostic valueALIVE studyClinic visitsPrognostic valueRisk groupsT lymphocytesAIDS casesLate failureDrug useHIVAIDSMonths
1987
T Cells in Multiple Sclerosis and Inflammatory Central Nervous System Diseases
Hafler D, Weiner H. T Cells in Multiple Sclerosis and Inflammatory Central Nervous System Diseases. Immunological Reviews 1987, 100: 307-332. PMID: 3326824, DOI: 10.1111/j.1600-065x.1987.tb00537.x.Peer-Reviewed Original ResearchConceptsT cellsInflammatory responseCNS tissueInflammatory central nervous system diseasesProgressive multiple sclerosis patientsCentral nervous system diseaseClass II MHC antigensMonoclonal antibodiesT-cell receptor gene rearrangementsCSF T cellsOngoing inflammatory responseTotal T cellsInflammatory CNS diseaseMultiple sclerosis patientsAntigen-presenting cellsAnti-measles antibodiesChronic disease processesAntigen-specific cellsNervous system diseasesReceptor gene rearrangementsMurine monoclonal antibodiesSelective accumulationAlpha beta chainsCNS damageSclerosis patients
1979
Thymosin immunotherapy in patients with small cell carcinoma of the lung. Correlation of in vitro studies with clinical course
Lipson S, Chretien P, Makuch R, Kenady D, Cohen M. Thymosin immunotherapy in patients with small cell carcinoma of the lung. Correlation of in vitro studies with clinical course. Cancer 1979, 43: 863-870. PMID: 218717, DOI: 10.1002/1097-0142(197903)43:3<863::aid-cncr2820430313>3.0.co;2-5.Peer-Reviewed Original ResearchConceptsTotal T cellsPretreatment CEA levelsT cellsCEA levelsClinical courseCellular immunityTumor responsePretreatment levelsCarcinoembryonic antigenAdministration of thymosinIntensive chemotherapy programsPeripheral blood levelsSmall cell carcinomaDuration of responseOverall tumor responseThymus-dependent lymphocytesLarger patient populationType of treatmentP groupMechanism of actionComplete remissionT60 groupChemotherapy programBronchogenic carcinomaImmune defects
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply